Citations

Showing 10 of 108104 citations.

Maintenance rituximab or observation after frontline treatment with bendamustine‐rituximab for follicular lymphoma
Hill, Brian T. , Winter, Allison , Becnel, Melody , Cerhan, James R. , Link, Brian K. , Maurer, Matthew J. , Fakhri, Bita , Reddy, Prathima, Smith, Stephen D. , Mukhija, Dhruvika , Jagadeesh, Deepa , Desai, Amrita, Alderuccio, Juan Pablo , Lossos, Izidore S. , Mehra, Pooja , Portell, Craig A. , Goldman, Max L. , Calzada, Oscar , Cohen, Jonathon B. , Hussain, Mohammad Junaid, Tiutan, Timothy , Martin, Peter , Kodali, Abhigna, Evens, Andrew M. , Becnel, Melody R , Cerhan, James R , Link, Brian K , Maurer, Matthew , Calzada, Oscar , Martin, Peter , Evens, Andrew M , Hill, Brian , Fakhri, Bita , Portell, Craig A , Nastoupil, Loretta J. , Habermann, Thomas M. , Ghosh, Nilanjan , Caimi, Paolo F. , Kahl, Brad S.

Mayo Clinic

British Journal of Haematology | December 21, 2018 | Volume: 184 | Issue: 4 | Pages: 524-535

10.1111/bjh.15720 | PMID 30575016 Get It

SummaryBendamustine (B) with rituximab (R) is a standard frontline treatment for medically fit follicular lymphoma (FL) patients. The safety and efficacy of maintenance rituximab (MR) after BR induction has not been formally compared to observation for FL, resulting in disparate practice patterns. Prospective trials have shown benefit of MR after R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or R‐CVP (rituximab, cyclophosphamide, vincristine, prednisone), yet recent data from the GALLIUM study comparing outcomes of patients treated with chemotherapy with R or obinutuzumab (G) showed higher than anticipated fatal adverse events with BR/BG. In order to assess the efficacy and tolerability of MR after BR, we retrospectively collected data on 640 newly diagnosed patients treated with FL. We found that patients who achieved partial remission (PR) after ≥4 cycles of BR had improved duration of response (DOR) with MR vs. no maintenance, whereas those in complete remission did not. These findings were confirmed in a validation cohort. In the entire study population, the known fatal adverse event rate after BR was 2·5% and did not significantly differ in those receiving MR versus no maintenance. [Correction added on 14 January 2019, after online publication: The preceding sentence has been corrected in this current version.] Within the limitations inherent to retrospective analysis, these data suggest that FL patients with a PR to BR experience prolongation of remission with MR with an acceptable safety profile.
Can MRI contribute to pulmonary nodule analysis?
Koo, Chi Wan , Lu, Aiming , Takahashi, Edwin A. , Simmons, Curtis , Geske, Jennifer R. , Wigle, Dennis A. , Peikert, Tobias, Simmons, Curtis L, Wigle, Dennis, Takahashi, Edwin A , Geske, Jennifer

Mayo Clinic

Journal of Magnetic Resonance Imaging | December 21, 2018 | Volume: 49 | Issue: 7 | Pages: No page available

10.1002/jmri.26587 | PMID 30575193 Get It

BackgroundThere is no accurate method distinguishing different types of pulmonary nodules.PurposeTo investigate whether multiparametric 3T MRI biomarkers can distinguish malignant from benign pulmonary nodules, differentiate different types of neoplasms, and compare MRI‐derived measurements with values from commonly used noninvasive imaging modalities.Study TypeProspective.SubjectsSixty‐eight adults with pulmonary nodules undergoing resection.SequencesRespiratory triggered diffusion‐weighted imaging (DWI), periodically rotated overlapping parallel lines with enhanced reconstruction (PROPELLER) fat saturated T2‐weighted imaging, T1‐weighted 3D volumetric interpolated breath‐hold examination (VIBE) using CAIPIRINHA (controlled aliasing in parallel imaging results in a higher acceleration).Assessment/StatisticsApparent diffusion coefficient (ADC), T1, T2, T1 and T2 normalized to muscle (T1/M and T2/M), and dynamic contrast enhancement (DCE) values were compared with histology to determine whether they could distinguish malignant from benign nodules and discern primary from secondary malignancies using logistic regression. Predictability of primary neoplasm types was assessed using two‐sample t‐tests. MRI values were compared with positron emission tomography / computed tomography (PET/CT) to examine if they correlated with standardized uptake value (SUV) or CT Hounsfield unit (HU). Intra‐ and interreader agreements were assessed using intraclass correlations.ResultsForty‐nine of 74 nodules were malignant. There was a significant association between ADC and malignancy (odds ratio 4.47, P < 0.05). ADC ≥1.3 μm2/ms predicted malignancy. ADC, T1, and T2 together predicted malignancy (P = 0.003). No MRI parameter distinguished primary from metastatic neoplasms. T2 predicted PET positivity (P = 0.016). T2 and T1/M correlated with SUV (P < 0.05). Of 18 PET‐negative malignant nodules, 12 (67%) had an ADC ≥1.3 μm2/ms. With the exception of T2, all noncontrast MRI parameters distinguished adenocarcinomas from carcinoid tumors (P < 0.05). T1, T2, T1/M, and T2/M correlated with HU and therefore can predict nodule density. Combined with ADC, washout enhancement, arrival time (AT), peak enhancement intensity (PEI), Ktrans, Kep, Ve collectively were predictive of malignancy (P = 0.012). Combined washin, washout, time to peak (TTP), AT, and PEI values predicted malignancy (P = 0.043). There was good observer agreement for most noncontrast MRI biomarkers.Data ConclusionMRI can contribute to pulmonary nodule analysis. Multiparametric MRI might be better than individual MRI biomarkers in pulmonary nodule risk stratification.Level of Evidence: 1Technical Efficacy: Stage 2J. Magn. Reson. Imaging 2018.
External Quality Assurance of Platelet Function Assays: Results of the College of American Pathologists Proficiency Testing Program
Chandler, Wayne L. , Brown, Alan F., Chen, Dong , Moser, Karen , Olson, John D. , Smock, Kristi J. , Volod, Oksana , Higgins, Russell A. , Pham, Huy Phu, Chen, Dong , Brown, Alan F., Pham, Huy P.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | December 21, 2018 | Volume: 143 | Issue: 4 | Pages: 472-482

10.5858/arpa.2017-0556-cp | PMID 30920864 Get It

Context.— The College of American Pathologists (CAP) developed proficiency testing for platelet function assays by using blood collected by the participant added to challenge tubes containing either saline (normal) or tirofiban (abnormal). Objective.— To analyze platelet function proficiency testing for Platelet Function Analyzer PFA-100, platelet aggregation, PlateletWorks, and PlateletMapping. Design.— Proficiency testing data from 2012–2016 were analyzed. Results.— For PFA-100, a total of 1200 laboratories participated; the coefficient variation (CV) of cartridge closure times was 22% (saline); 44,952 of 45,616 survey responses (99%) provided an interpretation, and 42,934 of 44,952 (96%) were correct. For optical platelet aggregation, 190 laboratories participated; the CV was 17% (saline), 7444 of 7813 survey responses (95%) provided an interpretation, and 7015 of 7444 (94%) were correct. For PlateletWorks, 60 laboratories participated; the CV was 3% to 11% (saline); 2412 of 2454 survey responses (98%) provided an interpretation, and 1207 of 1276 (95%) were correct for adenosine diphosphate (ADP) and 936 of 1136 (82%) for collagen. For PlateletMapping, 200 laboratories participated. For ADP, 1128 of 2697 survey responses (42%) provided an interpretation, but only 927 of 1128 (82%) were correct. For arachidonic acid, 1139 of 2604 survey responses (44%) provided an interpretation and 964 of 1139 (85%) were correct. Conclusions.— CAP is the first to provide proficiency testing for platelet aggregation, PlateletWorks, and PlateletMapping. Platelet aggregation, PFA-100, and PlateletWorks using ADP as an agonist performed well with more than 90% of laboratories providing an interpretation and a similar number providing correct results. PlateletWorks using collagen and PlateletMapping showed worse interpretive accuracy than the other methods.
Is Hip Arthroscopy Effective in Patients With Combined Excessive Femoral Anteversion and Borderline Dysplasia? A Match-Controlled Study
Chaharbakhshi, Edwin O., Hartigan, David E. , Perets, Itay , Domb, Benjamin G.

Mayo Clinic

The American Journal of Sports Medicine | December 21, 2018 | Volume: 47 | Issue: 1 | Pages: 123-130

10.1177/0363546518812859 | PMID 30781991 Get It

Background: Appropriate patient selection is critical when hip arthroscopy is considered in the setting of borderline dysplasia (BD). It is presumable that excessive femoral anteversion (EFA) and BD may contraindicate arthroscopy. Hypothesis: Patients with combined EFA and BD (EFABD) demonstrate significantly inferior short-term outcomes after arthroscopic labral preservation and capsular closure when compared with a similar control group with normal lateral coverage and femoral anteversion. Study Design: Cohort study; Level of evidence, 3. Methods: Data were prospectively collected and retrospectively reviewed on patients undergoing hip arthroscopy between April 2010 and November 2014. The EFABD group’s inclusion criteria were BD (lateral center-edge angle, 18°-25°), labral tear, capsular closure, and femoral version ≥20°, as well as preoperative modified Harris Hip Score, Nonarthritic Hip Score, Hip Outcome Score–Sports Specific Subscale, and visual analog scale. Exclusion criteria were workers’ compensation, preoperative Tönnis grade >1, microfracture, abductor pathology, or previous ipsilateral hip surgery or conditions. Patients in the EFABD group were matched 1:2 to a similar control group with normal coverage and femoral anteversion by age at surgery ± 6 years, sex, body mass index ± 5, acetabular Outerbridge grade (0, 1 vs 2, 3, 4), and iliopsoas fractional lengthening. Results: Sixteen EFABD cases were eligible for inclusion, and 100% follow-up was obtained at ≥2 years postoperatively. Twelve EFABD cases were matched to 24 control cases. Mean femoral version was 22.4° in the EFABD group and 10.2° in the control group ( P = .01). Mean lateral center-edge angle was 22.1° in the EFABD group and 31.5° in the control group ( P < .0001). Acetabuloplasty was performed significantly more frequently in the control group ( P = .0006). No other significant differences were found regarding demographics, findings, procedures, or preoperative scores. At latest follow-up, the EFABD group demonstrated significantly lower mean modified Harris Hip Score (76.1 vs 85.9; P = .005), Nonarthritic Hip Score (74.8 vs 88.5; P < .0001), Hip Outcome Score–Sports Specific Subscale (58.3 vs 78.4; P = .02), and patient satisfaction (7.1 vs 8.3; P = .005). There were 4 secondary surgical procedures (33.3%) in the EFABD group and 1 (4.2%) in the control group ( P = .03). One patient in each group required arthroplasty. Conclusion: Patients treated with arthroscopic labral preservation and capsular closure in the setting of EFABD demonstrated significant improvements from presurgery to latest follow-up. However, their results are significantly inferior when compared with a matched-controlled group. Consideration of periacetabular osteotomy or femoral osteotomy may be warranted in the setting of EFABD to achieve optimal benefit.
Faculty Opinions recommendation of Cartilage-penetrating nanocarriers improve delivery and efficacy of growth factor treatment of osteoarthritis.
Evans, Christopher H.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | December 21, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.734511389.793554411 Get It

Why we need to report more than 'Data were Analyzed by t-tests or ANOVA'
Weissgerber, Tracey L. , Valencia, Oscar A. Garcia , Milić, Nataša , Winham, Stacey J. , Garcia-Valencia, Oscar , Garovic, Vesna D , Winham, Stacey J , Weissgerber, Tracey L , Milic, N , Garovic, Vesna D.

Mayo Clinic

eLife | December 21, 2018 | Volume: 7 | Issue: No issue available | Pages: No page available

10.7554/elife.36163 | PMID 30574870 Get It

Transparent reporting is essential for the critical evaluation of studies. However, the reporting of statistical methods for studies in the biomedical sciences is often limited. This systematic review examines the quality of reporting for two statistical tests, t-tests and ANOVA, for papers published in a selection of physiology journals in June 2017. Of the 328 original research articles examined, 277 (84.5%) included an ANOVA or t-test or both. However, papers in our sample were routinely missing essential information about both types of tests: 213 papers (95% of the papers that used ANOVA) did not contain the information needed to determine what type of ANOVA was performed, and 26.7% of papers did not specify what post-hoc test was performed. Most papers also omitted the information needed to verify ANOVA results. Essential information about t-tests was also missing in many papers. We conclude by discussing measures that could be taken to improve the quality of reporting.
Cancer rehabilitation as an essential component of quality care and survivorship from an international perspective
Smith, Sean R. , Zheng, Jasmine , Haig, Andrew J. , Silver, Julie , Silver, Julie K. , Cheville, Andrea

Mayo Clinic

Disability and Rehabilitation | December 21, 2018 | Volume: 42 | Issue: 1 | Pages: 8-13

10.1080/09638288.2018.1514662 | PMID 30574818 Get It

Baseline Impedance Measured During High-resolution Esophageal Impedance Manometry in Patients With Rumination Syndrome is as Abnormal as in Patients With GERD
Halland, Magnus , Nelson, Holly A, Katzka, David A. , Ravi, Karthik , Nelson, Holly A, Talley, Nicholas J. , Crowell, Michael D.

Mayo Clinic

Journal of Clinical Gastroenterology | December 21, 2018 | Volume: 54 | Issue: 1 | Pages: 28-34

10.1097/mcg.0000000000001159 | PMID 30575633 Get It

Goals and Background: Baseline impedance measured during high-resolution impedance manometry (HRIM) can distinguish patients with gastroesophageal reflux disease (GERD) from controls, presumably due to differences in esophageal acid exposure. The characteristics of regurgitation and reflux in rumination syndrome and GERD are very different, and thus we investigated whether baseline esophageal impedance would differ in these 2 patient groups compared with controls. Study: We compared 20 patients with rumination syndrome with 20 patients who had GERD and 40 controls. Baseline impedance was measured over 15 seconds during the landmark period of HRIM in all 18 impedance sensors on a HRIM catheter. Results: The mean distal baseline impedance measured in ohms during HRIM was 1336 Ω [95% confidence interval (CI)=799, 1873) in patients with GERD, 1536 Ω in rumination syndrome (95% CI=1012, 2061), and 3379 Ω in controls (95% CI=2999, 3759) (P<0.0001). Proximal impedance was significantly lower in the GERD and rumination groups compared with controls; rumination syndrome (2026; 95% CI=1493, 2559 Ω), GERD (2572; 95% CI=2027, 3118 Ω), and controls (3412; 95% CI=3026, 3798 Ω) (P<0.001). Conclusions: Baseline impedance measured during HRIM in patients with rumination syndrome is significantly lower than controls and appears similar to patients with GERD both in the proximal and distal esophagus. These findings suggest that the postprandial regurgitation in rumination syndrome alters both the distal and proximal esophageal mucosal barrier.
Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma
Winden, Annemieke W. J. Opstal‐van, Haan, Hugoline G. de , Hauptmann, Michael , Schmidt, Marjanka K. , Russell, Nicola S. , Janus, Cécile P.M. , Krol, Augustinus D. G. , Baan, Frederieke H. van der , Bruin, Marie L. De , Eggermond, Anna M. van, Haiman, Christopher A., Sawyer, Elinor J. , Hooning, Maartje J. , Peto, Julian , Orr, Nick , Easton, Douglas F. , Strong, Louise C. , Cooke, Rosie, Swerdlow, Anthony J. , Leeuwen, Flora E. van , de Haan, Hugoline G , De Bruin, Marie L , Dennis, Joe , Pharoah, Paul D P , Swerdlow, Anthony J , Schmidt, Marjanka K , Broeks, Annegien , Anton‐Culver, Hoda , Cox, Angela , Devilee, Peter , Couch, Fergus J. , Pharoah, Paul D.P. , Aleman, Berthe M.P. , Bhatia, Smita , Robison, Leslie L. , Sawyer, Elinor J , Orr, Nick

Mayo Clinic

Blood | December 21, 2018 | Volume: 133 | Issue: 10 | Pages: 1130-1139

10.1182/blood-2018-07-862607 | PMID 30573632 Get It

AbstractFemale Hodgkin lymphoma (HL) patients treated with chest radiotherapy (RT) have a very high risk of breast cancer. The contribution of genetic factors to this risk is unclear. We therefore examined 211 155 germline single-nucleotide polymorphisms (SNPs) for gene-radiation interaction on breast cancer risk in a case-only analysis including 327 breast cancer patients after chest RT for HL and 4671 first primary breast cancer patients. Nine SNPs showed statistically significant interaction with RT on breast cancer risk (false discovery rate, &lt;20%), of which 1 SNP in the PVT1 oncogene attained the Bonferroni threshold for statistical significance. A polygenic risk score (PRS) composed of these SNPs (RT-interaction-PRS) and a previously published breast cancer PRS (BC-PRS) derived in the general population were evaluated in a case-control analysis comprising the 327 chest-irradiated HL patients with breast cancer and 491 chest-irradiated HL patients without breast cancer. Patients in the highest tertile of the RT-interaction-PRS had a 1.6-fold higher breast cancer risk than those in the lowest tertile. Remarkably, we observed a fourfold increased RT-induced breast cancer risk in the highest compared with the lowest decile of the BC-PRS. On a continuous scale, breast cancer risk increased 1.4-fold per standard deviation of the BC-PRS, similar to the effect size found in the general population. This study demonstrates that genetic factors influence breast cancer risk after chest RT for HL. Given the high absolute breast cancer risk in radiation-exposed women, these results can have important implications for the management of current HL survivors and future patients.